ÇÁ·Î±×·¥
4¿ù 9ÀÏ(±Ý) / DAY 1 | |||
08:00~08:30 | Registration | ||
08:30~09:20 | Opening Session : Àå±â±âÁõ ¹× À̽ÄÀÇ ÇöÀç¿Í ¹ßÀü¹æÇâ | ÁÂÀå : ÇÏÁ¾¿ø (¼¿ïÀÇ´ë), ¼°æ¼® (¼¿ïÀÇ´ë) |
|
08:30~08:40 | Opening | ¡¡ | |
08:40~09:00 | 2020³âµµ Àå±â±âÁõ ¹× ÀÌ½Ä ÇöȲ | ¹®Àμº (Çѱ¹Àå±âÁ¶Á÷±âÁõ¿ø) | |
09:00~09:20 | Àå±â±âÁõ ¹× ÀÌ½Ä È°¼ºÈ ¹æ¾È | ¹é°æ¼ø (º¸°Çº¹ÁöºÎ Ç÷¾×Àå±âÁ¤Ã¥°ú) | |
09:20~09:30 | Break | ¡¡ | |
09:30~11:00 | Basic Session ¥° : Vaccines and neutralizing antibodies to SARS-CoV-2 | ÁÂÀå: Á¤ÁØÈ£ (¼¿ï´ë), ¾çÀç¼® (¼¿ïÀÇ´ë) |
|
09:30~10:00 | SARS-CoV-2 Biology and Drug Development | ±è½ÂÅà (Çѱ¹ÆĽºÅ𸣿¬±¸¼Ò) | |
10:00~10:30 | IVT mRNA ¿Í À̸¦ Àü´ÞÇϱâÀ§ÇÑ LNP Á¦Çü | ÀÌÇõÁø (ÀÌÈ¿©´ë) | |
10:30~11:00 | Stereotypic neutralizing VH antibodies against SARS-CoV-2 in patients with COVID-19 and healthy individuals | ³ëÁø¼º (¼¿ï´ë) | |
09:30~11:00 | Reviewer ÀÎÁõ ±³À° ¥° | ÁÂÀå: ¿ÀÀºÁö (°¡Å縯ÀÇ´ë), Çã¼± (ÇѸ²ÀÇ´ë) |
|
09:30~09:40 | ÀÎÁõ ±³À° °úÁ¤ ¹× KJT ÇöȲ ¼Ò°³ | À±ÀÍÁø (°Ç±¹ÀÇ´ë) | |
09:40~10:10 | Ethics for Peer Reviewers | Çѵ¿¼ö (ÇѾçÀÇ´ë) | |
10:10~10:40 | Personal Data Protection (Publication Consent) | ÀÌÀº¼Ò (¾ÆÁÖÀÇ´ë) | |
10:40~11:00 | Áú¹®°ú ÅäÀÇ | ||
11:00~11:10 | Break | ¡¡ | |
11:10~12:40 | Basic Session ¥± : Antibodies in transplantation : Therapeutics and discovery | ÁÂÀå: ±èÈ¿¸® (¼¿ï¾Æ»êº´¿ø), ±è¹ü¼® (¿¬¼¼ÀÇ´ë) |
|
11:10~11:40 | Designing the diversity of synthetic antibody libraries | ½ÉÇöº¸ (ÀÌÈ¿©´ë) | |
11:40~12:10 | Fc Receptors in Immunity | ÀÌâÇÑ (¼¿ï´ë) | |
12:10~12:40 | Vascular Cell Adhesion Molecule-1 as a Novel Emerging Target in Allograft Rejection for Monoclonal Antibody Therapy | À̼®¹¬ (±¹¹Î´ë) | |
11:10~12:40 | Reviewer ÀÎÁõ ±³À° ¥± | ÁÂÀå: À±ÀÍÁø (°Ç±¹ÀÇ´ë), ±è¼ö¿µ (ÇѸ²ÀÇ´ë) |
|
11:10~11:35 | Reviewer°¡ ¾Ë¾Æ¾ß ÇÒ ÀÇÇÐÅë°è | ¾ÈÇüÁø (°í·ÁÀÇ´ë) | |
11:35~12:00 | ¿¬±¸ Design ÀûÀý¼º Æò°¡ | ±èâ¼ö (¿¬¼¼ÀÇ´ë) | |
12:00~12:25 | ÀÇÆíÇù ÃâÆÇÀ±¸®À§¿øȸ ½ÉÀÇ ÇöȲ | ±èÀ¯¼± (ÀÎÁ¦ÀÇ´ë) | |
12:25~12:40 | Áú¹®°ú ÅäÀÇ | ||
11:00~11:10 | Break | ¡¡ | |
Focused Symposium |
12:45~13:45 | Focused Symposium ¥° | ÁÂÀå : Çã±ÔÇÏ (¿¬¼¼ÀÇ´ë) |
12:45~13:45 | Efficacy and Safety of Everolimus With Reduced-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Results from the TRANSFORM study | ÀÌÁÖÇÑ (¿¬¼¼ÀÇ´ë) | |
13:45~13:50 | Break | ¡¡ | |
13:50~15:20 | Basic session ¥² : Imaging platform technology | ÁÂÀå: ±è¼®¿µ (¼¿ï¾Æ»êº´¿ø), Çã±ÔÇÏ (¿¬¼¼ÀÇ´ë) |
|
13:50~14:20 | Advances in optical Imaging of immune monitoring | ±è»ó¿± (¼¿ï¾Æ»êº´¿ø) | |
14:20~14:50 | Immune microenvironment and in vivo imaging | Á¤±âÈÆ (¼¿ï´ëÇб³º´¿ø) | |
14:50~15:20 | Biomedical optical imaging technologies for preclinical / clinical applications | ±èÁرâ (¼¿ï¾Æ»êº´¿ø) | |
13:50~15:20 | ±³À° Session : Àå±â ¹× Á¶Á÷ ±âÁõÀÇ ½ÇÁ¦ ¾÷¹« | ÁÂÀå: À¯Èñö (ÀüºÏÀÇ´ë), À̱¤¿õ (¼¿ïÀÇ´ë) |
|
13:50~14:05 | KONOSÀÇ ¾÷¹« | ±è¼ø¿µ (±¹¸³Àå±âÁ¶Á÷Ç÷¾×°ü¸®¿ø) | |
14:05~14:20 | KODAÀÇ ¾÷¹« | ÀÌÁ¤¸² (Çѱ¹Àå±âÁ¶Á÷±âÁõ¿ø) | |
14:20~14:35 | Á¶Á÷±âÁõ ¹× ó¸® °úÁ¤ | ¿À½Ã¿µ (»ï¼º¼¿ïº´¿ø Àå±âÀ̽ļ¾ÅÍ) | |
14:35~14:50 | ½ÇÁ¦ ±âÁõ ¾÷¹« ¼öÇà½Ã ¾î·Á¿î Á¡ | ±èÇü¼÷ (ÄÚµð³×ÀÌÅÍ ÇùȸÀå) | |
14:50~15:20 | Panel discussion | ÁÖµ¿Áø (¿¬¼¼ÀÇ´ë), À̱ٵ¿ (¿ï»êÀÇ´ë), ¼Õ¼±¿µ (°³²¼¼ºê¶õ½ºº´¿ø) |
|
15:20~15:30 | Break | ¡¡ | |
15:30~17:00 | Á¤Ã¥ Session : Àå±âµî À̽Ŀ¡ °üÇÑ ¹ý·ü °³Á¤¾È Áß ³íÁ¡ | ÁÂÀå: ÇÏÁ¾¿ø (¼¿ïÀÇ´ë), ±Ç¿ÀÁ¤ (ÇѾçÀÇ´ë) |
|
15:30~15:55 | ¹Ì¼º³âÀÚ »ýü ±âÁõÇöȲ°ú ¹®Á¦Á¡ | À̳²ÁØ (¼¿ïÀÇ´ë) | |
15:55~16:20 | »ç¸ÁÀÇ Á¤ÀÇ¿Í º¯È³»¿ë | ¾ÈÇüÁØ (°æÈñÀÇ´ë) | |
16:20~16:45 | Àå±â±âÁõ ½Ã½ºÅÛÀÇ ÇöȲ°ú ÇâÈÄ º¯È | ±èµ¿½Ä (°í·ÁÀÇ´ë) | |
16:45~17:00 | Discussion | ¡¡ | |
17:00~17:10 | Closing | ||
17:10~17:40 | ÀÓ½ÃÀÌ»çȸ |
4¿ù 10ÀÏ(Åä) / DAY 2 | |||
08:00~08:30 | Registration | ||
08:30~09:30 | ¿¬±¸ °úÁ¦ º¸°í¥° | ÁÂÀå: ±è¸í¼ö (¿¬¼¼ÀÇ´ë), ¾È±Ô¸® (±¹¸³Áß¾ÓÀÇ·á¿ø) |
|
08:30~08:45 | û¼Ò³â´ë»ó »ý¸í³ª´® ±³À° Ä¿¸®Å§·³ ¿î¿µ | ¿ÀÁöÀº (ÇѸ²ÀÇ´ë) | |
08:45~09:00 | ±¹³» ³ú»çÀÚ Àå±â ±âÁõ È°¼ºÈ ¹× ¹Ù¶÷Á÷ÇÑ ±âÁõÀÚ ¿¹¿ì¸¦ À§ÇÑ °úÁ¦ | ¾ÈÇüÁØ (°æÈñÀÇ´ë) | |
09:00~09:15 | Àå±âÀ̽ÄÄÚµð³×ÀÌÅÍÀÇ ºÒÈ®½Ç¼º¿¡ ´ëÇÑ Àγ»·ÂÀÌ ÀÌÁ÷Àǵµ¿¡ ¹ÌÄ¡´Â ¿µÇâ: ¼ÒÁø°ú ±×¸´ÀÇ ¿ªÇÒ | À̼ö¶õ (°æ³²´ëÇб³) | |
09:15~09:30 | ¾Æ½Ã¾Æ Àå±âÀÌ½Ä ·¹Áö½ºÆ®¸® ¼³¸³ ¿¬±¸ | Á¤Á¾Ã¶ (KOTRY) | |
09:30~09:35 | Break | ¡¡ | |
09:35~10:35 | ¿¬±¸ °úÁ¦ º¸°í¥± | ÁÂÀå : ¹éȿä (¿¬¼¼ÀÇ´ë), ÀÌ»óÈ£ (°æÈñÀÇ´ë) |
|
09:35~09:55 | The effects of heat preconditioning during Ex Vivo Lung Perfusion in rat model | ÇÔ¼®Áø (¾ÆÁÖÀÇ´ë) | |
09:55~10:15 | ±¹³»ÆóÀÌ½Ä È¯ÀÚ¿¡¼ ÆóÀ̽ÄÈÄ »õ·ÎÀÌ ¹ß»ýÇÑ °ø¿©ÀÚ Æ¯ÀÌ Ç× HLA Ç×ü°¡ ¸¸¼ºµ¿Á¾ÀÌ½Ä ºÎÀü¿¡ ¹ÌÄ¡´Â ¿µÇâ | ±è¼ÛÀÌ (¿¬¼¼ÀÇ´ë) | |
10:15~10:35 | ±¹³» DCD µµÀÔÀ» À§ÇÑ guideline/protocol Á¦¾ÈÀ» À§ÇÑ °úÁ¦ | ÀÌÀç¸í (°í·ÁÀÇ´ë) | |
10:35~10:40 | Break | ¡¡ | |
10:40~11:40 | Plenary Session | ÁÂÀå : ±è¼øÀÏ (¿¬¼¼ÀÇ´ë), ±è»óÀÏ (°¡Å縯ÀÇ´ë) |
|
10:40~11:40 | COVID-19 vaccination in transplant recipient | ½ÅÀÇö (KAIST) | |
11:40~11:50 | Break | ¡¡ | |
11:50~12:10 | General Assembly | ||
12:10~12:20 | Break | ¡¡ | |
Focused Symposium |
12:20~13:20 | Focused Symposium ¥± | ÁÂÀå : ¼°æ¼® (¼¿ïÀÇ´ë) |
12:20~13:20 | ABO Ç÷¾×Çü ºÎÀûÇÕ °£À̽Ŀ¡¼ AMRÀÇ Áø´Ü°ú Ä¡·á | ¼Û±â¿ø (¼¿ï¾Æ»êº´¿ø) | |
12:20~13:20 | Focused Symposium ¥² | ÁÂÀå : Çã±ÔÇÏ (¿¬¼¼ÀÇ´ë) | |
12:20~12:50 | Impact of Lymphocyte Anti-Metabolite Immunosuppressions on Donor-Specific Anti-HLA Antibody and Kidney Graft Outcome : Open-label, Multi-center, Single arm, Phase 4 Trial (DoSAKOM Study) | À̼öÇü (¾ÆÁÖÀÇ´ë) | |
12:50~13:20 | Multi-center, Non-Comparative, Phase IV Study to Evaluate the Efficacy and Safety of Once-daily Prolonged Release Tacrolimus Capsule(TacroBell¢ç SR cap.) in Kidney Transplant Recipients. (OPIRUS Study) | ÀÌÁÖÇÑ (¿¬¼¼ÀÇ´ë) | |
12:20~13:20 | Focused Symposium ¥³ | ÁÂÀå : ÀÌÁ¾¼ö (¿ï»êÀÇ´ë) | |
12:20~12:50 | Tailored approaches for low risk KT patients with Low dose Thymoglobulin | ¹Ú¼øö (°¡Å縯ÀÇ´ë) | |
12:50~13:20 | Preventing Delayed Graft Function in High Risk Renal Transplantation | ¹Î»óÀÏ (¼¿ïÀÇ´ë) | |
12:10~12:20 | Break | ¡¡ | |
Concurrent Symposium |
13:30~15:00 | Concurrent Symposium ¥°(Kidney/Pancreas 1) | ÁÂÀå: ÀÌ»óÈ£ (°æÈñÀÇ´ë), ¹ÚÀç¹ü (¼º±Õ°üÀÇ´ë) |
13:30~14:00 | Current outcomes of kidney re-transplantation | ½ÅÈ£½Ä (°í½ÅÀÇ´ë) | |
14:00~14:30 | Pre-transplant evaluation and preparation | Á¤º´ÇÏ (°¡Å縯ÀÇ´ë) | |
14:30~15:00 | Post-transplant management | ±è¿µÈÆ (¿ï»êÀÇ´ë) | |
13:30~15:00 | Concurrent Symposium ¥± (Liver 1) | ÁÂÀå: ±è±âÈÆ (¿ï»êÀÇ´ë), À¯¿µ°æ (°¡Å縯ÀÇ´ë) |
|
13:30~13:45 | LT for non-HCC malignancy | ±èÁ¾¸¸ (¼º±Õ°üÀÇ´ë) | |
13:45~14:00 | Current status and future challenges in liver transplantation for NASH | ÃÖ¿µ·Ï (¼¿ïÀÇ´ë) | |
14:00~14:15 | An age limit on LT : Controversies and considerations | ¹Ú±æÃá (¿ï»êÀÇ´ë) | |
14:15~14:30 | Current status of DDLT for alcoholic liver disease in Korea in MELD era | ÁÖµ¿Áø (¿¬¼¼ÀÇ´ë) | |
14:30~15:00 | Panel discussion | ÇÑ¿µ¼® (°æºÏÀÇ´ë), ·ùÁ¦È£ (ºÎ»êÀÇ´ë), ÃÖÈ£Áß (°¡Å縯ÀÇ´ë), Á¤µ¿È¯ (¿ï»êÀÇ´ë) |
|
13:30~15:00 | Concurrent Symposium ¥² (Lung) - Long term cares after lung transplant | ÁÂÀå: ±è¿µÅ (¼¿ïÀÇ´ë), Àü°æ¸¸ (¼º±Õ°üÀÇ´ë) |
|
13:30~13:50 | Indication of re-transplant | ÀÌÁø±¸ (¿¬¼¼ÀÇ´ë) | |
13:50~14:10 | Malignancies after lung transplant | ¿©ÇýÁÖ (ºÎ»êÀÇ´ë) | |
14:10~14:30 | Follow-up strategies after lung transplantation | ¹Ú¼ºÈÆ (ÇѸ²ÀÇ´ë) | |
14:30~15:00 | Panel discussion | ÃÖ¼¼ÈÆ (¿ï»êÀÇ´ë), ±èµµÇü (ºÎ»êÀÇ´ë), ±è¼ÛÀÌ (¿¬¼¼ÀÇ´ë) |
|
15:00~15:10 | Break | ||
Concurrent Symposium |
15:10~16:40 | Concurrent Symposium ¥³ (Kidney/Pancreas 2) | ÁÂÀå : ±è¿µÈÆ (ÀÎÁ¦ÀÇ´ë), ÃÖ¼öÁø³ª (Àü³²ÀÇ´ë) |
15:10~15:40 | Measures to improve cardiovascular outcomes of diabetic kidney transplant patients | ÀÌÁ¤Ç¥ (¼¿ïÀÇ´ë) | |
15:40~16:10 | Impact of renin-angiotensin system blockade on outcomes | ±è´ö±â (¿¬¼¼ÀÇ´ë) | |
16:10~16:40 | Monitoring adherence of immunosuppressive agents | Á¤Èñ¿¬ (°æºÏÀÇ´ë) | |
15:10~16:40 | Concurrent Symposium ¥´ (Coordinator) | ÁÂÀå : È«Á¤ÀÚ (¼¿ï¾Æ»êº´¿ø), ±èº¹³à (»ï¼º¼¿ïº´¿ø) |
|
15:10~16:15 | À̽ÄȯÀÚÀÇ Äڷγª °ü·Ã ÃֽŠÁö°ß | ÀÌ»ó¿À (¿ï»êÀÇ´ë) | |
16:15~16:40 | ½ÅÀåÀÌ½Ä È¯ÀÚÀÇ ÀçÈ°¿îµ¿ | ¼Õ¼±¿µ (°³²¼¼ºê¶õ½ºº´¿ø) | |
15:10~16:40 | Concurrent Symposium ¥µ (Heart) - Patient care after heart transplantation: The life goes on | ÁÂÀå: ±èÀçÁß (¿ï»êÀÇ´ë), ¼º±âÀÍ (¼º±Õ°üÀÇ´ë) |
|
15:10~15:30 | Blood pressure after heart transplantation | ÀÌÇØ¿µ (¼¿ïÀÇ´ë) | |
15:30~15:50 | Exercise physiology after heart transplantation | ÀÌ»ó¾ð (¿ï»êÀÇ´ë) | |
15:50~16:10 | Pregnancy after heart transplantation | ±è´Ù·¡ (¼º±Õ°üÀÇ´ë) | |
16:10~16:40 | Panel discussion | ±èÀÎö (°è¸íÀÇ´ë), ¼Õ¼®È£ (¼¿ïÀÇ´ë), Á¤¼ºÈ£ (¾Æ»êº´¿ø), ¿ÀÀç¿ø (¼¼ºê¶õ½ºº´¿ø), À±Á¾Âù (¼¿ï¼º¸ðº´¿ø), ÇöÁØÈ£ (¿ï»êÀÇ´ë) |
|
17:00~17:15 | Closing |